Broadhollow Bioscience Park is revitalizing Long Island's life sciences sector. With Estee Lauder as a new anchor tenant and Dan Polner as executive director, the park is set to expand. Governor Kathy Hochul’s Long Island Investment Fund (LIIF) recently allocated $60 million to bolster local biotech startups and research institutions. Plans for a new 60,000-square-foot facility aim to strengthen collaborations with top institutions like Brookhaven National Laboratory and Stony Brook University. These initiatives position Broadhollow to drive innovation, create jobs, and boost the regional economy.
Long Island's biotechnology sector has faced numerous challenges, but recent developments offer a fresh opportunity. Estée Lauder's decision to become the new anchor tenant at Broad Hollow Bioscience Park brings renewed hope, with plans for research labs and 31 new jobs. However, the region’s biotech ambitions have historically faltered, with past setbacks including the departures of Helicon Therapeutics and OSI Pharmaceuticals. To turn this new chance into long-term success, Long Island must attract more life sciences firms, leverage local research resources, and foster strong regional collaboration. The next five years will be pivotal in determining whether this latest effort can finally build a thriving biotech industry.
Gov. Andrew M. Cuomo has signed a bill enabling OSI Pharmaceuticals Inc. to expand its operations at Farmingdale State College. The legislation, which passed with overwhelming support in the State Senate and Assembly, establishes the boundaries for the college's Broad Hollow Bioscience Park at 38.5 acres and allows for the construction of a third building. This new structure will house start-up companies while OSI expands into an existing building. The move is expected to create 135 jobs at the college, bolstering Long Island's biotechnology sector.
State senators have approved a bill to expand the business incubator at Farmingdale State College, a significant move aimed at boosting the local biotechnology sector. The legislation designates 38.5 acres for the Broad Hollow Bioscience Park and facilitates the construction of a third building to house start-up companies, with OSI Pharmaceuticals expanding into an existing second building. OSI, known for its lung cancer drug Tarceva, plans to create approximately 135 new jobs. The bill also exempts park tenants from state construction and procurement laws, simplifying development processes. This expansion is expected to drive economic growth and innovation in Long Island's biotechnology industry.